Compare EMBC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMBC | RNA |
|---|---|---|
| Founded | 1924 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.9M | 222.5M |
| IPO Year | 2021 | 2025 |
| Metric | EMBC | RNA |
|---|---|---|
| Price | $5.15 | $12.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $18.50 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 1.6M | 106.6K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.88% | N/A |
| EPS Growth | ★ 20.90 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.17 | $88.12 |
| Revenue Next Year | N/A | $18.11 |
| P/E Ratio | $4.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.77 | $11.13 |
| 52 Week High | $15.55 | $73.06 |
| Indicator | EMBC | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 74.48 | 53.98 |
| Support Level | $3.01 | $11.95 |
| Resistance Level | $9.38 | $14.05 |
| Average True Range (ATR) | 0.31 | 0.34 |
| MACD | 0.17 | 0.12 |
| Stochastic Oscillator | 96.51 | 87.08 |
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.